Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/9821
Title: | Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. | Austin Authors: | Schnurr, Max;Toy, Tracey;Shin, Amanda;Wagner, Moritz;Cebon, Jonathan S ;Maraskovsky, Eugene | Affiliation: | Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria 3084, Australia | Issue Date: | 14-Oct-2004 | Publication information: | Blood 2004; 105(4): 1582-9 | Abstract: | The interleukin-12 (IL-12) cytokine family plays important roles in the orchestration of innate and adaptive immunity by dendritic cells (DCs). The regulation of IL-12 expression has been thoroughly studied, but little is known about factors governing the expression of IL-23 and IL-27, 2 novel IL-12 family members acting on memory and naive T cells, respectively. We report that the expression of these cytokines by DCs was critically dependent on the mode of activation. DC activation by CD40L predominantly induced IL-12. Ligands of the Toll-like receptor (TLR) 3 and TLR4 induced IL-12 and IL-27, whereas exposure to intact Escherichia coli resulted in high expression of IL-12, IL-27, and IL-23. The nucleotide adenosine triphosphate (ATP) has been shown to inhibit IL-12 production by P2 receptors. We found that ATP also inhibited IL-27 expression but enhanced IL-23 expression. Interestingly, the reciprocal regulation of IL-12/IL-27 and IL-23 by ATP was mediated by 2 distinct P2 receptors and was also induced by prostaglandin E(2) by cyclic adenosine monophosphate (cAMP)-elevating EP2/EP4 receptors. As a consequence, DCs were selectively impaired in their ability to induce interferon-gamma (IFN-gamma) in naive T cells but continued to promote IFN-gamma and IL-17 production in memory T cells. These studies identify P2 receptors as promising targets for the design of novel strategies to manipulate specific stages of T-cell responses and to treat IL-12- and IL-23-mediated disorders. | Gov't Doc #: | 15486065 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/9821 | DOI: | 10.1182/blood-2004-05-1718 | Journal: | Blood | URL: | https://pubmed.ncbi.nlm.nih.gov/15486065 | Type: | Journal Article | Subjects: | Adenosine Triphosphate.pharmacology.physiology Animals Cells, Cultured Cyclic AMP.physiology Dendritic Cells.immunology.metabolism.secretion Down-Regulation.immunology Escherichia coli.immunology Extracellular Space.metabolism.physiology G0 Phase.immunology Humans Immunologic Memory Interferon-gamma.antagonists & inhibitors.biosynthesis Interleukin-12.antagonists & inhibitors.biosynthesis Interleukin-23 Interleukin-23 Subunit p19 Interleukins.biosynthesis.secretion Mice Monocytes.immunology.metabolism.secretion Orthomyxoviridae.immunology Receptors, Purinergic P2.physiology Signal Transduction.immunology T-Lymphocyte Subsets.cytology.immunology.metabolism Up-Regulation.immunology |
Appears in Collections: | Journal articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
15486065.pdf | 358 kB | Adobe PDF | ![]() View/Open |
Page view(s)
6
checked on Dec 10, 2023
Download(s)
96
checked on Dec 10, 2023
Google ScholarTM
Check
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.